32 / 140
154
REFERENCIAS BIBLIOGRÁFICAS
1.
Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
Clinical Practice Guideline for the Evaluation and Management of
Chronic Kidney Disease. Kidney Int. Suppl. 2013; 3:1-150.
2.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risk
of death, cardiovascular events, and hospitalizations. N Engl J Med.
2004; 351:1296-1305.
3.
Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risks of cardiovascular
events, death, and heart failure in diabetic and nondiabetic individuals.
JAMA. 2001; 286:421-426.
4.
Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and
mortality risk: A systematic review. J Am Soc Nephrol. 2006; 17.2034-
2047.
5.
Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk
for cardiovascular disease, renal replacement, and death in the United
States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;
16:489-95.
6.
Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal
disease in randomized controlled trials of cardiovascular disease. JAMA.
2006; 296: 1377-1384.
7.
U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of
chronic kidney disease and end stage renal disease in the United States.
National Institutes of Health, National Institutes of Diabetes, Digestive
and Kidney Disease.
8.
Goldstein BA, Arce CM, Hlatky MA, et al. Trends in the incidence of atrial
fibrillation in older patients initiating dialysis in the United States.
Circulation. 2012;126: 2293-2301.
9.
Matsushita K, van der Velde M, Astor BC, et al, for the CKD Prognosis
Consortium. Association of estimated glomerular filtration rate and
albuminuria with all-cause and cardiovascular mortality in general
population cohorts: a collaborative meta-analysis. Lancet 2010;
375:2073–2081.
10. Van der Velde M, Matsushita K, Coresh J, et al, for the Chronic Kidney
Disease Prognosis Consortium. Lower estimated glomerular filtration
rate and higher albuminuria are associated with all-cause and
cardiovascular mortality. A collaborative meta-analysis of high-risk
population cohorts. Kidney Int. 2011; 79:1341–1352.
11. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse
epidemiology of cardiovascular risk factors in maintenance dialysis
patients. Kidney Int. 2003; 63:793-808.
12. Foley RN, Herzog CA, Collins AJ: Smoking and cardiovascular outcomes
in dialysis patients: The United States Renal Data SystemWave 2 study.
Kidney Int. 2003; 63:1462-1467.
13. Levin A, Singer J, Thompson CR, et al. Prevalent LVH in the predialysis
population: Identifying opportunities for intervention. Am J Kidney Dis
1996; 27:347–54.
14. Fox CS, Matsushita K, Woodward M, et al.: Associations of kidney disease
measures with mortality and end-stage renal disease in individuals with
and without diabetes: A meta-analysis. Lancet 2012; 380:1662-1673.
15. Mahmoodi BK, Matsushita K, Woodward M, et al.: Associations of
kidney disease measures with mortality and end-stage renal disease
in individuals with and without hypertension: A meta-analysis. Lancet
2012; 380:1649-1661.
16. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in
uremia: Oxidant stress as a unifying concept of cardiovascular disease
in uremia. Kidney Int. 2002; 62:1524-1538.
17. Mechanisms of endothelial dysfunction in resistance arteries from
patients with end-stage renal disease. PLoS One 2012; 7:e36056.
18. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum
phosphorus and calcium x phosphate product with mortality risk in
chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;
31:607-617.
19. Sharma R, Pellerin D, Gaze DC, et al.: Mitral annular calcification
predicts mortality and coronary artery disease in end stage renal
disease. Atherosclerosis 2007; 191:348-354.
20. Vonesh EF, Snyder JJ, Foley RN, Collins AJ: The differential impact of risk
factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int.
2004; 66:2389-2401.
21. Herzog CA, Littrell K, Arko C, et al.: Clinical characteristics of dialysis
patients with acute myocardial infarction in the United States: A
collaborative project of the United States Renal Data System and
the National Registry of Myocardial Infarction. Circulation 2007;
116:1465-1472.
[REV. MED. CLIN. CONDES - 2015; 26(2) 142-155]
CONCLUSIONES
En los pacientes con ERC, comparados con la población general,
la enfermedad CV es más frecuente y severa y generalmente es
sub-diagnosticada y sub-tratada. Los pacientes con ERC deben
ser vistos como un grupo de alto riesgo cardiovascular, similar a
la diabetes y requieren de una atención clínica especial a nivel
individual, en el desarrollo de guías clínicas y en el impulso
de estudios clínicos específicos a esta población. La potente
asociación causal entre ERC y enfermedad CV hace impera-
tivo prevenir el progreso de la ERC, ya que con ello se reduce
El autor declara no tener conflictos de interés, en relación a este artículo.
el riesgo cardiovascular. En los pacientes con ERC la causa de
este riesgo cardiovascular elevado es multifactorial, explicada
en parte por procesos fisiopatológicos propios. Por este motivo
la estrategia estándar, dirigida a controlar los factores de riesgo
tradicionales, no tiene la misma efectividad. Por lo tanto se
deben explorar estrategias innovadoras, centradas en los meca-
nismos fisiopatológicos propios de esta población, sin olvidar
que es vital iniciar la prevención en forma precoz y enfocar el
tratamiento de estos pacientes de forma multifactorial y bajo un
equipo multidisciplinario.